C12N 2740/10023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2740/10023 (Virus like particles [vlp]) appears on 25 US grants and 48 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 48
- Assignees
- 33
- Inventors
- 74
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 3 |
| 2020 | 0 | 3 |
| 2021 | 3 | 4 |
| 2022 | 1 | 7 |
| 2023 | 2 | 1 |
| 2024 | 4 | 14 |
| 2025 | 10 | 7 |
| 2026 | 2 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Methods and kits for quantifying the removal of mock virus particles from a purified solution17 Feb 2026US 12,553,894 B2Cygnus Technologies, L.L.C.
- VLP-based monovalent ebola vaccines and methods of making and using same30 Sep 2025US 12,427,190 B2Children's Hospital Medical Center
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells2 Sep 2025US 12,404,525 B2President and Fellows of Harvard College
- Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells2 Sep 2025US 12,404,527 B2Selexs S.A.
- Improved expression of surface-displayed antigens1 Oct 2026US 2026/0295030 A1Inprother Aps
- Use of rtl8-deficient cells to produce biocompatible, peg10-derived virus-like particles (vlp)30 Jul 2026US 2026/0218135 A1The Regents of the University of Colorado, a body corporate
- Transduction of gammadelta T cells with pseudotyped retroviral vectors28 May 2026US 2026/0146260 A1Miltenyi Biotec GmbH
- Nucleic acids encoding human endogenous retrovirus k (herv-k) envelope proteins containing modified immunosuppressive domains (isd) and uses thereof19 Mar 2026US 2026/0077031 A1Inprother Aps
- Methods and products for genetic engineering11 Dec 2025US 2025/0376492 A1Centre National de la Recherche Scientifique (CNRS)
Most cited
By later US patents
- Methods and products for genetic engineering23US 10,968,253 B2Centre National de la Recherche Scientifique (CNRS) · 2021
- Methods and products for genetic engineering9US 11,649,264 B2Centre National de la Recherche Scientifique (CNRS) · 2023
- Vaccine for use in the prophylaxis and/or treatment of a disease7US 11,351,247 B2Inprother Aps · 2022
- Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles4US 9,632,087 B2MockV Solutions, Inc. · 2017
- Antibodies against chikungunya virus and uses thereof3US 9,902,765 B2Blood Systems Research Institute · 2018